Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2010
05/20/2010CA2743266A1 Pumpkin and rose hips weight loss composition
05/20/2010CA2743264A1 Tetrasubstituted pyridazines hedgehog pathway antagonists
05/20/2010CA2743242A1 P70 s6 kinase inhibitor and mtor inhibitor combination therapy
05/20/2010CA2743232A1 Crystalline forms of fingolimod hcl
05/20/2010CA2743146A1 Heteroaryl diamide compounds useful as mmp-13 inhibitors
05/20/2010CA2743073A1 2,4-diaminopyrimidine derivates as ptk2- inhibitors for the treatment of abnormal cell growth
05/20/2010CA2743019A1 Akt and p70 s6 kinase inhibitors
05/20/2010CA2743015A1 Pi3k/mtor kinase inhibitors
05/20/2010CA2743006A1 Inclusion complexes of pinocembrin with cyclodextrin or its derivatives
05/20/2010CA2742993A1 Pyrazine compounds as phosphodiesterase 10 inhibitors
05/20/2010CA2742922A1 Novel pyrazolone-derivatives and their use as pd4 inhibitors
05/20/2010CA2742921A1 Octenidine composition
05/20/2010CA2742856A1 Acenaphtho heterocycle compounds, cyclodextrin inclusion compounds and complexes, and uses in the manufactures of bh3 protein analogue, bcl-2 family protein inhibitors thereof
05/20/2010CA2742846A1 Releasable fusogenic lipids for nucleic acids delivery systems
05/20/2010CA2742833A1 Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
05/20/2010CA2742824A1 Derivatives of hypoestoxides for the treatment of malaria
05/20/2010CA2742783A1 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
05/20/2010CA2742771A1 Modification of amyloid-beta load in non-brain tissue
05/20/2010CA2742679A1 Biphenylacetamide derivatives
05/20/2010CA2742520A1 [4- (1-amino-ethyl) -cyclohexyl] -methyl-amines as antibacterials
05/20/2010CA2742486A1 Gamma secretase modulators
05/20/2010CA2742472A1 Gamma secretase modulators
05/20/2010CA2742297A1 Pyridine, bicyclic pyridine and related analogs as sirtuin modulators
05/20/2010CA2742114A1 Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
05/20/2010CA2742105A1 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
05/20/2010CA2741974A1 Salts of fingolimod
05/20/2010CA2741096A1 Triterpenoid 2-deoxy glycosides, method of preparation thereof and use thereof as medicaments
05/20/2010CA2741018A1 Spiro-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulenes
05/20/2010CA2740864A1 Naphthylacetic acids
05/20/2010CA2740863A1 Naphthylacetic acids
05/20/2010CA2740389A1 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors
05/20/2010CA2740338A1 Compound useful for treating cellulite
05/20/2010CA2740262A1 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
05/20/2010CA2739732A1 Organic nutrient salts, methods of preparation and uses
05/20/2010CA2739725A1 Naphthylacetic acids used as crth2 antagonists or partial agonists
05/20/2010CA2738885A1 Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
05/20/2010CA2738884A1 Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
05/20/2010CA2738883A1 Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
05/20/2010CA2737587A1 Quinazoline derivatives as nk3 receptor antagonists
05/19/2010EP2186913A2 Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
05/19/2010EP2186901A2 Mutations in the BCR-Abl-tyrosine kinase associated with resistance to STI-571
05/19/2010EP2186836A1 Cosmetic, pharmaceutical and dermatological medium.
05/19/2010EP2186819A1 Novel glucopyranose esters and glucofuranose esters of alkyl- fumarates and their pharmaceutical use
05/19/2010EP2186818A1 Chemical synthesis of phosphatidylinositol mannoside glycans form mycobacterium tuberculosis
05/19/2010EP2186814A1 Sulfonyl-substituted carbapenem compounds
05/19/2010EP2186811A1 Synthesis of epothilones, intermediates thereto, analogues and uses thereof
05/19/2010EP2186810A1 Poly-heteroaryl derivatives for the treatment of cancer
05/19/2010EP2186809A1 New crystal form of sunitinib malate
05/19/2010EP2186808A1 Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
05/19/2010EP2186807A1 Process for the Preparation of Esomeprazole Magnesium Dihydrate
05/19/2010EP2186806A1 Flavanone compound and uses thereof
05/19/2010EP2186803A2 Substituted thioacetamides
05/19/2010EP2186800A1 New mandelic acid derivatives and their use as thrombin inhibitors
05/19/2010EP2186795A1 (1s, 2s, 3s, 4r)-3-ý(1s)-1-acetylamino-2-ethyl-butyl¨-4-guanidino-2- hydroxyl-cyclopentyl-1-carboxylic acid hydrates and pharmaceutical uses thereof
05/19/2010EP2186793A1 Substituted Tetracycline Compounds
05/19/2010EP2186792A1 2-(a-hydroxypentyl) benzoate and its preparation and use
05/19/2010EP2186789A1 Method of producing reduced coenzyme q10 and method of stabilizing the same
05/19/2010EP2186530A1 Promoters exhibiting endothelial cell specificity and methods of using same
05/19/2010EP2186528A1 Pharmaceutical containing hif-1 alpha and hif-2 alpha expression inhibitor
05/19/2010EP2186523A1 Use of escin for treatment of Type IV hypersensitivity reaction
05/19/2010EP2186521A1 Compositons for the treatment and prevention of diseases involving bacterial, viral and fungal pathogens and fragments thereof with polyvinylpyrrolidone and/or polyvinylpolypyrrolidone as therapeutically active compound
05/19/2010EP2186520A1 Therapeutic agent for fibromyalgia syndrome and therapeutic agent for pain due to vascular smooth muscle spasm
05/19/2010EP2186519A1 Use of adenosine aspartate for the preparation of pharmaceutical products for the treatment of liver cancer
05/19/2010EP2186518A1 Composition and methods for treatment of disorders of protein aggregation
05/19/2010EP2186517A1 Use and methods of use for an antagonist of the serotin3 receptor (5-ht3) and a selective modulator of chloride channels for the treatment of addiction to or dependence on medicines/drugs or nervous system disorders
05/19/2010EP2186516A1 Novel benzazepine derivative
05/19/2010EP2186515A1 Pharmaceutical composition comprising the combination of an anti-depressive agent and an ansiolytic agent for control and treatment of depressive disorders
05/19/2010EP2186514A1 Treatment of Malignant Peripheral Nerve Sheath Tumors
05/19/2010EP2186513A1 Use of specific cyclolignans
05/19/2010EP2186512A1 Use of allylcysteine or its analogs and pharmaceutical composition threrof
05/19/2010EP2186511A1 Method of treating sleep disorders using eplivanserin
05/19/2010EP2186509A2 Propofol transparent anaesthetic solution with low venous irritation
05/19/2010EP2186508A2 Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
05/19/2010EP2186507A2 A liquid pharmaceutical formulation comprising nicotine for the administration to the oral cavity
05/19/2010EP2186419A1 NMP-containing extract, a method of its production and uses thereof
05/19/2010EP2185700A2 Antisense microrna and uses therefor
05/19/2010EP2185580A1 Lactation-associated polypeptides
05/19/2010EP2185574A2 Antibodies and related molecules that bind to 24p4c12 proteins
05/19/2010EP2185572A1 Substituted arylsulfonylaminomethylphosphonic acid derivatives, their preparation and their use in the treatment of type i and ii diabetes mellitus
05/19/2010EP2185571A1 Substituted arylsulfonylaminomethylphosphonic acid derivatives, their preparation and their use in the treatment of type i and ii diabetes mellitus
05/19/2010EP2185570A2 Novel activators of glucokinase
05/19/2010EP2185568A2 Therapeutic compounds
05/19/2010EP2185567A2 Substituted bicyclolactam compounds
05/19/2010EP2185562A1 Pyrrolopyrimidines
05/19/2010EP2185561A2 1,2,3,4-tetrahydropyrroloý1,2-a¨pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrroloý1,2-a¨ý1,4¨-diazépine-7-carboxamide derivatives, preparation and therapeutic use thereof
05/19/2010EP2185559A1 Crystalline form of a dihydropteridione derivative
05/19/2010EP2185558A1 Tricyclic n-heteroaryl-carboxamide derivatives, preparation thereof and therapeutic use of same
05/19/2010EP2185557A2 Perharidines as cdk inhibitors
05/19/2010EP2185556A1 Imidazopyridine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
05/19/2010EP2185555A1 Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
05/19/2010EP2185553A1 Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
05/19/2010EP2185552A1 Dipeptoid prodrugs and the use thereof
05/19/2010EP2185551A2 Prodrugs of 2-amino-6-( { [2-(4-chlorphenyl)-1,3-thiazol-4-yl] methyl}thio)-4-[4-(2-hy-droxyethoxy) phenyl] pyridin-3, 5-dicarbonitrile
05/19/2010EP2185550A1 Substituted aryloxazoles and the use thereof
05/19/2010EP2185549A1 Antimicrobial ortho-fluorophenyl oxazolidinones for treatment of bacterial infections
05/19/2010EP2185546A1 Co-crystals and pharmaceutical compositions comprising the same
05/19/2010EP2185544A2 N-azacyclic substituted pyrrole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 for the treatment of diabetes and metabolic disorders
05/19/2010EP2185543A2 Method for splitting omeprazole salts
05/19/2010EP2185542A2 Substituted quinoline derivatives as h1 receptor antagonists
05/19/2010EP2185541A1 Substituted phenylenediamines as inhibitors of the interaction between mdm2 and p53
1 ... 2261 2262 2263 2264 2265 2266 2267 2268 2269 2270 2271 2272 2273 2274 2275 2276 2277 2278 2279 2280 2281 ... 7860